Physician profile
William Nason
NPI 1932194776
$8,362.47
in general payments reported to CMS, 2019-2025
31 companies · $802 in 2025
The $802 reported for 2025 was more than what 85% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,986 · 2020: $282 · 2021: $331 · 2022: $743 · 2023: $676 · 2024: $542 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,920 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,920.49 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,676.69 | 2019-2022 | |
| Abbvie INC. | $681.37 | 2019-2024 | |
| Astellas Pharma US INC | $427.45 | 2022-2025 | Veozah, Myrbetriq |
| Biogen, INC. | $338.31 | 2023-2025 | Zurzuvae |
| Pfizer INC. | $268.86 | 2019-2024 | |
| Organon LLC | $259.56 | 2021-2025 | Nexplanon, Jada System |
| Bayer Healthcare Pharmaceuticals INC. | $193.96 | 2020-2025 | |
| Mayne Pharma Commercial LLC | $159.12 | 2022-2025 | |
| Coopersurgical, INC. | $145.15 | 2019-2025 | Paragard T 380a, Mara Console |
| Therapeuticsmd, INC. | $133.85 | 2020-2022 | |
| Mylan Pharmaceuticals INC. | $101.06 | 2019-2022 | |
| Millicent US INC | $99.90 | 2022-2025 | Intrarosa, Femlyv, Femring |
| Amgen INC. | $87.91 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $83.41 | 2019-2020 | |
| Shield Therapeutics INC | $80.99 | 2024-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $74.41 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $70.18 | 2019-2025 | Aptima |
| Exeltis, USA INC. | $60.64 | 2024-2025 | Slynd |
| Allergan, INC. | $56.08 | 2019 | |
| Myriad Women'S Health, INC. | $52.99 | 2023 | Myrisk |
| Agile Therapeutics, INC. | $48.15 | 2022 | |
| Daiichi Sankyo INC. | $46.20 | 2022 | |
| Sumitomo Pharma America, INC. | $39.77 | 2025 | Myfembree |
| Baxter Healthcare | $35.78 | 2025 | Perclot |
| Evofem Biosciences, INC. | $26.49 | 2021-2022 | |
| Myovant Sciences INC. | $25.97 | 2022 | |
| Lupin INC. | $24.73 | 2019-2020 | |
| Gynesonics, INC. | $22.45 | 2022 | |
| Avanos Medical | $15.35 | 2019 | |
| Medtronic, INC. | $13.11 | 2023 | Truclear |
| Avion Pharmaceuticals | $12.58 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Nason listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.